Residency · Residency · Nephrology

Hemodialysis - Principles and Vascular Access

Introduction

Hemodialysis is the most widely used renal replacement therapy modality worldwide, accounting for approximately 90 percent of dialysis patients in the United States. The procedure requires an extracorporeal blood circuit, a semipermeable membrane housed within a dialyzer, and a dialysate solution of defined composition flowing countercurrent to blood. The standard prescription involves sessions of three to four hours performed three times per week, though alternative schedules including short daily hemodialysis and nocturnal hemodialysis are increasingly recognized for their superior outcomes. Adequate dialysis delivery, measured by validated kinetic models, is a critical determinant of morbidity and mortality reduction in the end-stage kidney disease population.

Principles of Solute Removal

Diffusion

Diffusion is the primary mechanism by which small solutes are cleared during hemodialysis. Molecules such as urea, creatinine, potassium, and phosphorus move passively across the semipermeable membrane from the compartment of higher concentration (blood) to the compartment of lower concentration (dialysate), driven entirely by the concentration gradient between the two compartments. Several factors govern the efficiency of diffusive clearance. The concentration gradient itself is the principal driving force and is maintained throughout the length of the dialyzer by countercurrent flow, in which blood and dialysate travel in opposite directions. This design ensures that even as solute concentrations begin to equilibrate, the blood exiting the dialyzer still encounters relatively fresh dialysate, thereby maximizing the gradient along the entire fiber length. Membrane surface area and membrane permeability, quantified by the mass transfer area coefficient (KoA), directly influence how much solute can cross per unit time. Higher blood flow rates (Qb) deliver more solute to the membrane per unit time, while higher dialysate flow rates (Qd) maintain the concentration gradient on the dialysate side by rapidly removing transferred solute. Molecular weight is an additional determinant: smaller molecules diffuse more rapidly than larger ones, which is why urea (60 Da) is cleared far more efficiently by diffusion than middle molecules such as beta-2 microglobulin (11,800 Da).

Convection

Convection refers to the removal of solute by solvent drag, in which solute molecules are carried across the membrane along with water that is being ultrafiltered under a hydrostatic pressure gradient. The transmembrane pressure, or TMP, drives water across the membrane, and dissolved solutes are swept along with it. Convective clearance is substantially more effective for middle molecules, including beta-2 microglobulin, phosphorus, and inflammatory cytokines, than diffusion alone. This principle underlies two important modalities. Hemofiltration relies entirely on convection, with no dialysate used; instead, large volumes of replacement fluid are infused either before the filter (pre-dilution) or after the filter (post-dilution) to compensate for the removed ultrafiltrate. Hemodiafiltration (HDF) combines both diffusion and convection, achieving superior middle molecule clearance while retaining efficient small solute removal. The landmark CONVINCE trial, published in 2023, demonstrated that online HDF with high convection volumes of 23 liters or more per session reduced all-cause mortality by 23 percent compared to high-flux hemodialysis. Achieving these convection volumes requires high blood flow rates of at least 350 mL/min and a well-functioning vascular access capable of sustaining such flows.

Ultrafiltration

Ultrafiltration is the net removal of water from blood across the dialysis membrane into the dialysate compartment. The driving force is the transmembrane pressure, calculated as the difference between hydrostatic pressures on the blood and dialysate sides minus the oncotic pressure exerted by plasma proteins. The ultrafiltration rate (UFR) is prescribed to remove the fluid that has accumulated between dialysis sessions, representing the interdialytic weight gain. However, the rate at which fluid is removed has important clinical consequences. Data from the Dialysis Outcomes and Practice Patterns Study (DOPPS) have shown that ultrafiltration rates exceeding 13 mL/kg/hr are independently associated with increased mortality, likely reflecting hemodynamic stress, myocardial stunning, and end-organ ischemia during aggressive fluid removal. Sodium profiling, in which the dialysate sodium concentration is varied during the session, and ultrafiltration profiling, in which the rate of fluid removal is adjusted throughout the treatment, have been employed to reduce intradialytic hypotension. However, these strategies remain controversial, as sodium profiling may increase interdialytic thirst and weight gain, potentially negating the hemodynamic benefit.

<image>Schematic diagram of a hemodialysis circuit showing the complete extracorporeal blood path. Start at the arterial needle (or arterial port of catheter) showing blood drawn by the blood pump at Qb 300-450 mL/min. Show the blood passing through the dialyzer (hollow fiber membrane with thousands of parallel fibers), with dialysate flowing in the opposite direction (countercurrent) at Qd 500-800 mL/min. Label the three solute transport mechanisms across the membrane: diffusion (small molecules following concentration gradient), convection (middle molecules carried by ultrafiltration water), and ultrafiltration (net water removal driven by TMP). Show the venous return through the air detector and venous clamp back to the patient. Include the dialysate circuit with proportioning system, heating (37°C), degassing, and spent dialysate to drain. Label heparin infusion point, arterial and venous pressure monitors, and dialysate composition (Na 138-140, K 2-3, Ca 2.5-3.0, HCO3 35-40, glucose 100-200 mg/dL).</image>

Dialyzer and Membrane Characteristics

Membrane Types

The evolution of dialyzer membranes reflects decades of advances in biocompatibility and clearance efficiency. Cellulose-based membranes such as cuprophane, the earliest membrane material, are now largely obsolete because they provoke significant complement activation and bioincompatibility reactions. Modified cellulose membranes, including cellulose acetate and hemophan, offered improved biocompatibility but have also been superseded. The current standard of care employs synthetic membranes made from polysulfone, polyethersulfone, polyacrylonitrile, or polymethylmethacrylate (PMMA). These synthetic membranes provide excellent biocompatibility with minimal complement activation and can be manufactured with a range of pore sizes to achieve desired clearance characteristics.

A critical distinction among modern dialyzers is between high-flux and low-flux membranes. High-flux membranes have larger pore sizes, higher ultrafiltration coefficients (KUf), and superior clearance of middle molecules such as beta-2 microglobulin. The HEMO study, published in 2002, compared high-flux to low-flux membranes in a randomized trial and found no overall mortality benefit with high-flux membranes, although subgroup analyses suggested a benefit in patients who had been dialyzing for more than 3.7 years. The MPO study in 2009 further demonstrated that high-flux membranes conferred a survival benefit in patients with serum albumin levels below 4 g/dL, a population characterized by inflammation and malnutrition.

Membrane Properties

Several quantitative properties characterize dialyzer performance. The KoA, or mass transfer coefficient multiplied by area, describes the diffusive clearance capacity of the membrane; a higher KoA translates to better small solute clearance. The ultrafiltration coefficient (KUf), expressed in mL/hr/mmHg, defines the membrane's water permeability: high-flux membranes typically have a KUf greater than 20, while low-flux membranes fall below 10. Surface area, ranging from 1.0 to 2.5 square meters across available dialyzers, determines the total exchange area; larger surface areas enhance clearance but also increase the extracorporeal blood volume, which may be relevant in hemodynamically fragile patients. The sieving coefficient, defined as the ratio of solute concentration in the ultrafiltrate to that in blood, ideally approaches 1.0 for freely permeable solutes such as urea and is progressively lower for larger molecules.

Dialysis Adequacy

Urea Kinetic Modeling

The adequacy of hemodialysis has historically been assessed through urea kinetic modeling, with Kt/V serving as the principal metric. In this formulation, K represents the dialyzer urea clearance, t is the treatment time, and V is the volume of urea distribution, which approximates total body water. The single-pool Kt/V (spKt/V) is calculated from pre- and post-dialysis blood urea nitrogen levels using the Daugirdas second-generation logarithmic formula: spKt/V = -ln(R - 0.008t) + (4 - 3.5R) x (UF/W), where R is the post-to-pre BUN ratio, t is the session time in hours, UF is the ultrafiltration volume in liters, and W is the post-dialysis weight in kilograms. KDOQI 2015 guidelines recommend a target spKt/V of at least 1.4 per session, with a minimum acceptable value of 1.2.

The urea reduction ratio (URR) provides a simpler alternative, calculated as (pre-BUN minus post-BUN) divided by pre-BUN, multiplied by 100, with a target of at least 65 percent. However, URR does not account for urea generated during dialysis or for ultrafiltration, making it a less precise measure than Kt/V.

The equilibrated Kt/V (eKt/V) accounts for post-dialysis urea rebound, a phenomenon in which BUN rises after dialysis as urea redistributes from tissue compartments into the blood. The eKt/V is approximately 0.2 units lower than the spKt/V, and a minimum target of 1.2 is recommended. For comparing different dialysis schedules, including conventional thrice-weekly, short daily, and nocturnal regimens, the weekly standardized Kt/V (stdKt/V) is employed, with a target of at least 2.3.

Limitations of Urea-Based Adequacy

Urea is a small molecule of only 60 Daltons, and its clearance does not reliably reflect the removal of middle molecules that contribute to the uremic syndrome. The adequacy targets derived from urea kinetics represent minimum thresholds rather than optimal values. Residual kidney function contributes meaningfully to overall clearance, and even a small amount of residual urine output confers survival benefit. Clinicians should strive to preserve residual kidney function by avoiding nephrotoxins, maintaining diuretics, and continuing ACE inhibitors or ARBs when tolerated. The HEMO study provided important context by demonstrating no mortality benefit when increasing the Kt/V target from 1.25 to 1.65 in conventional thrice-weekly hemodialysis, reinforcing the concept that chasing higher urea clearance alone does not improve outcomes.

Beyond Kt/V

Dialysis outcomes depend on far more than urea clearance. Volume management, phosphorus control, middle molecule removal, treatment time, frequency, ultrafiltration rate, and intradialytic hemodynamic stability all contribute to patient well-being and survival. The FREQUENT trial demonstrated that short daily hemodialysis (six sessions per week) significantly improved left ventricular hypertrophy and quality of life compared to conventional thrice-weekly schedules, even when the per-session Kt/V was not markedly different. This finding underscores that the dose-response relationship in dialysis extends well beyond what urea kinetics alone can capture, and that longer and more frequent treatments offer benefits through improved volume control, phosphorus removal, and hemodynamic stability.

Dialysate Composition

Standard Dialysate

The dialysate is a precisely formulated solution whose composition is designed to normalize the electrolyte and acid-base milieu of the patient's blood during each treatment. Sodium concentration is typically set at 138 to 140 mEq/L; higher sodium concentrations reduce intradialytic hypotension by maintaining plasma osmolality but promote thirst and increased interdialytic weight gain, creating a trade-off that must be individualized. Potassium is usually prescribed at 2 to 3 mEq/L, though concentrations as low as 1 mEq/L may be used for severe hyperkalemia and as high as 3 to 4 mEq/L for normokalemic patients. Data from DOPPS have shown that very low potassium baths below 2 mEq/L are associated with increased arrhythmia risk, likely from rapid intradialytic potassium shifts.

Calcium in the dialysate is typically 2.5 mEq/L (1.25 mmol/L) as the standard concentration, with higher concentrations of 3.0 mEq/L used for hypocalcemic patients and lower concentrations of 2.0 to 2.25 mEq/L for patients receiving calcimimetics or those at risk of vascular calcification. Bicarbonate, now universally used in place of the acetate-based dialysate that caused hemodynamic instability, is set at 35 to 40 mEq/L to correct metabolic acidosis. Glucose at 100 to 200 mg/dL prevents intradialytic hypoglycemia, and magnesium is maintained at 0.5 to 1.0 mEq/L.

Dialysate temperature is an important but often underappreciated variable. Cooled dialysate at 36 to 36.5 degrees Celsius, below the standard 37 degrees, reduces intradialytic hypotension by maintaining peripheral vascular tone and preventing heat-induced vasodilation. However, the MyTEMP trial in 2022 demonstrated that a personalized cooled dialysate strategy did not reduce major cardiovascular events compared to standard temperature dialysate, suggesting that the hemodynamic benefits of cooling may not translate into hard clinical endpoints.

Complications of Hemodialysis

Intradialytic Hypotension (IDH)

Intradialytic hypotension is the most common acute complication of hemodialysis, occurring in approximately 20 to 30 percent of sessions. It is defined as a systolic blood pressure drop of 20 mmHg or greater, or a mean arterial pressure drop of 10 mmHg or greater, accompanied by symptoms such as nausea, cramping, dizziness, or loss of consciousness. The pathophysiology is multifactorial: excessive ultrafiltration rates that outpace plasma refilling from the interstitial space, autonomic dysfunction particularly common in diabetic patients, underlying cardiac dysfunction with impaired compensatory responses, suboptimal antihypertensive medication timing, low dialysate sodium, warm dialysate promoting vasodilation, food ingestion during dialysis causing splanchnic vasodilation, and hypoalbuminemia reducing oncotic pressure and plasma refilling.

Acute management involves placing the patient in Trendelenburg position, administering 100 to 200 mL of normal saline as a bolus, and reducing the ultrafiltration rate. Preventive strategies include accurate dry weight assessment using bioimpedance spectroscopy, lung ultrasound, or inferior vena cava diameter measurement; limiting the ultrafiltration rate to below 13 mL/kg/hr; cooling the dialysate to 36 to 36.5 degrees Celsius; administering midodrine 5 to 10 mg prior to hemodialysis for refractory cases; sodium modeling; performing isolated ultrafiltration before diffusive dialysis; and extending treatment time to allow gentler fluid removal. Patients should be counseled to avoid taking antihypertensive medications before dialysis sessions.

Dialysis Disequilibrium Syndrome

Dialysis disequilibrium syndrome results from cerebral edema caused by rapid urea clearance in severely uremic patients. When blood urea is reduced rapidly during dialysis, a transient osmotic gradient develops between the blood and the brain, where urea equilibrates more slowly. This gradient drives water into brain cells, causing cerebral edema and increased intracranial pressure. Risk factors include the first dialysis session in a severely uremic patient, very high blood urea nitrogen levels exceeding 150 mg/dL, and the extremes of age (children and elderly patients). Symptoms range from headache, nausea, and restlessness to confusion, seizures, and coma in severe cases. Prevention is the cornerstone of management: the first dialysis session should be performed with a low blood flow rate of approximately 200 mL/min for only two hours, targeting a low Kt/V. High-sodium dialysate and prophylactic mannitol infusion may further reduce the osmotic gradient and mitigate cerebral edema.

Dialyzer Reactions

Dialyzer reactions are classified into two types based on their mechanism and severity. Type A reactions are true anaphylactic or anaphylactoid events that occur within the first 30 minutes of treatment, presenting with urticaria, dyspnea, and in severe cases, cardiovascular collapse and cardiac arrest. These reactions are mediated by hypersensitivity to ethylene oxide used as a membrane sterilant, by bradykinin generation when AN69 membranes are used in patients taking ACE inhibitors, or by complement activation with bioincompatible membranes. Type B reactions, sometimes called first-use syndrome, are milder events characterized by chest pain and back pain that are generally self-limiting. They are believed to result from complement activation and are most common with new, unprocessed dialyzers.

Air Embolism

Air embolism is a rare but potentially lethal complication that occurs when air enters the extracorporeal circuit through a catheter disconnection, a crack in the dialyzer, or failure of the air detection system. Even small volumes of air can obstruct the right ventricular outflow tract, causing acute dyspnea, chest pain, and cardiac arrest. Immediate management requires clamping the venous line to prevent further air entry, placing the patient in the left lateral decubitus position (the Durant maneuver) to trap air in the right atrium and prevent pulmonary outflow obstruction, and aspirating air from the venous catheter if accessible. Modern dialysis machines incorporate ultrasonic air detectors and automatic venous clamps that have greatly reduced the incidence of this complication.

Vascular Access

Arteriovenous Fistula (AVF)

The arteriovenous fistula remains the preferred vascular access for hemodialysis as endorsed by KDIGO and the Fistula First Initiative, though the approach has evolved to be more nuanced and patient-centered. An AVF is created by surgically anastomosing a native artery to a vein, resulting in arterialization of the vein with thickened walls and increased blood flow. Common configurations include the radiocephalic fistula (Brescia-Cimino fistula) at the wrist, the brachiocephalic fistula in the upper forearm or antecubital fossa, and the brachiobasilic fistula, which requires surgical transposition of the basilic vein to a superficial position for needle access.

The advantages of AVF are well established: it carries the lowest infection rate among all access types, provides the best long-term patency, and is associated with the lowest mortality. However, AVFs have significant disadvantages. Maturation requires a minimum of 6 to 12 weeks, and the "rule of 6s" provides clinical criteria for maturity: flow greater than 600 mL/min, vein diameter greater than 6 mm, depth less than 6 mm from the skin surface, and usable length greater than 6 cm. Primary failure rates remain substantial, with 20 to 60 percent of AVFs failing to mature to the point of clinical usability.

Complications of AVF include steal syndrome, in which arterial blood is diverted through the fistula at the expense of distal perfusion, causing hand ischemia. This is more common with proximal fistulas and is treated with the DRIL procedure (distal revascularization-interval ligation). Aneurysm and pseudoaneurysm formation result from repeated cannulation at the same site, whether by the rope-ladder or buttonhole technique. High-output cardiac failure is a rare but important complication that occurs when fistula flow exceeds 2 liters per minute, representing more than 20 percent of cardiac output, and necessitates fistula banding or revision.

Arteriovenous Graft (AVG)

An arteriovenous graft uses a synthetic conduit, most commonly expanded polytetrafluoroethylene (PTFE), to connect an artery to a vein. The principal advantage of AVG over AVF is the shorter time to usability, typically 2 to 4 weeks, and a higher technical success rate. Early cannulation grafts, designed to be accessed within 24 to 72 hours of placement, further reduce dependence on catheter-based access. However, AVGs carry higher rates of infection and thrombosis compared to AVFs, with a median patency of only 2 to 3 years. Thrombosis is the most common complication and is treated with thrombectomy, often combined with angioplasty of an underlying venous outflow stenosis.

Central Venous Catheter (CVC)

Central venous catheters provide immediate vascular access for hemodialysis and are classified as tunneled (permcath) or non-tunneled. Tunneled catheters are designed for extended use over weeks to months and incorporate a Dacron cuff within the subcutaneous tunnel that promotes tissue ingrowth and serves as a barrier to bacterial migration. Non-tunneled catheters are intended only for temporary access over days to weeks. The right internal jugular vein is the preferred insertion site because it provides a straight path to the right atrium and superior vena cava junction. The subclavian vein should be avoided whenever possible because of the significant risk of central venous stenosis, which can compromise the ipsilateral upper extremity for future AVF or AVG creation.

Catheter-related bloodstream infection (CRBSI) is the most serious complication of catheter-dependent hemodialysis, occurring at a rate of 2 to 5 infections per 1000 catheter-days. Prevention requires strict sterile technique during every catheter access per CDC guidelines, chlorhexidine-based exit site care, and catheter lock solutions. Standard heparin locks are used to maintain patency, while antimicrobial lock solutions containing gentamicin-citrate are employed in high-risk patients. When CRBSI is suspected, paired blood cultures drawn simultaneously from the catheter and a peripheral vein should be obtained before initiating empiric antibiotics. Empiric therapy consists of vancomycin for gram-positive coverage plus a gram-negative agent. Management decisions regarding catheter exchange over a guidewire versus catheter removal and replacement at a new site depend on the organism identified and the clinical response to antibiotics.

<image>Comparison of the three types of hemodialysis vascular access with clinical photographs and diagrams. Panel 1: Arteriovenous fistula (AVF) - show a diagram of a radiocephalic (wrist) fistula with the radial artery anastomosed to the cephalic vein, the arterialized vein with thickened walls and palpable thrill, and two needle insertion points for arterial and venous cannulation. Include maturation criteria (rule of 6s). Panel 2: Arteriovenous graft (AVG) - show a PTFE graft loop in the forearm connecting the brachial artery to a forearm vein, with the synthetic material visible between the two needle insertion points. Panel 3: Tunneled central venous catheter (permcath) - show a tunneled catheter inserted via the right internal jugular vein with the Dacron cuff in the subcutaneous tunnel, the catheter tip at the right atrial-SVC junction, and the external arterial (red) and venous (blue) lumens. Include a comparison table below with infection rate, thrombosis rate, patency, maturation time, and 5-year mortality for each access type.</image>

Vascular Access Planning

The historical mantra of "Fistula First, Catheter Last" has evolved to a more individualized paradigm of "Right Access, Right Patient, Right Time." Access planning must consider patient age, life expectancy, vessel quality assessed by duplex ultrasound mapping, cardiac function, and hand dominance. Vessel mapping criteria generally require an arterial diameter of at least 2 mm and a vein diameter of at least 2.5 mm with tourniquet application, with no evidence of central venous stenosis. Some patients, particularly elderly individuals with limited life expectancy, poor vessels, or significant cardiac dysfunction, may be better served with an AVG rather than enduring multiple failed AVF creation attempts with prolonged catheter dependence. This nuanced approach prioritizes timely establishment of a functional, complication-free access tailored to the individual patient's clinical context and goals of care.

Alternative Hemodialysis Modalities

Home Hemodialysis

Home hemodialysis encompasses two principal schedules: short daily hemodialysis, performed five to six sessions per week for two to two and a half hours each, and nocturnal hemodialysis, performed three to six nights per week for six to eight hours. The FREQUENT trial demonstrated that daily hemodialysis improved left ventricular hypertrophy regression and quality of life, with a trend toward reduced mortality. These extended and more frequent regimens provide superior phosphorus control, better volume management, and greater hemodynamic stability compared to conventional in-center thrice-weekly schedules. Dedicated home hemodialysis machines, such as the NxStage System One (now marketed as Tablo) and other purpose-built systems, facilitate home treatment. Barriers to adoption include the need for a trained caregiver or partner, a training period of four to eight weeks, space requirements in the home, and the demands of ongoing vascular access maintenance.

Hemodiafiltration (HDF)

The CONVINCE trial in 2023 established high-volume online hemodiafiltration, defined as achieving convection volumes of 23 liters or more per session, as superior to high-flux hemodialysis for all-cause mortality reduction (23 percent relative risk reduction). Achieving these convection volumes requires specialized equipment, high blood flow rates, and a well-functioning arteriovenous access, as most catheters cannot sustain the necessary flow. Hemodiafiltration has long been the standard of care in many European countries and is gaining global adoption as the CONVINCE data are incorporated into clinical practice guidelines.

Key Clinical Pearls

• Ultrafiltration rate greater than 13 mL/kg/hr is independently associated with mortality; clinicians should extend dialysis time or add a fourth session rather than removing excessive fluid in three to four hours
• The CONVINCE trial establishes high-volume HDF as superior to conventional HD for mortality; this will likely shift practice toward HDF where infrastructure permits
• Right internal jugular vein is the preferred catheter insertion site; NEVER use the subclavian vein in a patient who may need future ipsilateral AV access (central vein stenosis risk)
• Kt/V is a minimum adequacy target, not an optimal one; overall dialysis quality depends on volume management, middle molecule clearance, phosphorus control, and treatment time
• Residual kidney function (RKF) contributes significantly to overall clearance and outcomes in incident dialysis patients; preserve RKF by avoiding nephrotoxins, maintaining diuretics, and continuing RAAS blockade

References

1. Blankestijn PJ, Vernooij RWM, Hockham C, et al. Effect of Hemodiafiltration or Hemodialysis on Mortality in Kidney Failure (CONVINCE). N Engl J Med. 2023;389(8):700-709.
2. FHN Trial Group. In-Center Hemodialysis Six Times per Week versus Three Times per Week (FREQUENT). N Engl J Med. 2010;363(24):2287-2300.
3. Eknoyan G, Beck GJ, Cheung AK, et al. Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis (HEMO Study). N Engl J Med. 2002;347(25):2010-2019.
4. Lok CE, Huber TS, Lee T, et al. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis. 2020;75(4 Suppl 2):S1-S164.
5. Daugirdas JT. Second generation logarithmic estimates of single-pool variable volume Kt/V. J Am Soc Nephrol. 1993;4(5):1205-1213.

Read this lecture as Markdown